|
|||||
|
|
Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study |
|
| Authors: | Andrew Spencer Andrew Roberts Nola Kennedy Christina Ravera Serge Cremers Sanela Bilic Terry Neeman Michael Copeman Horst Schran Kevin Lynch |
| Affiliation: | (1) Department of Haematology and Bone Marrow Transplantation, The Alfred Hospital, Prahan, Victoria, Australia;(2) Department of Haematology, Royal Melbourne Hospital, Parkville, Victoria, Australia;(3) Department of Clinical Pharmacology, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA;(4) Covance Pty. Ltd., Canberra, ACT, Australia;(5) Novartis Pharmaceuticals Australia Pty. Ltd., 54 Waterloo Rd, North RydeM, NSW, 2113, Australia |
| Abstract: | BackgroundCases of impaired renal function have been reported in patients who had been treated with both zoledronic acid and thalidomide for myeloma. Hence, we conducted a safety study of zoledronic acid and thalidomide in myeloma patients participating in a trial of maintenance therapy. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |